1. Home
  2. AURA vs BCYC Comparison

AURA vs BCYC Comparison

Compare AURA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

HOLD

Current Price

$6.54

Market Cap

429.2M

Sector

Health Care

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$5.05

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AURA
BCYC
Founded
2007
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
429.2M
360.7M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
AURA
BCYC
Price
$6.54
$5.05
Analyst Decision
Strong Buy
Buy
Analyst Count
4
10
Target Price
$19.00
$14.00
AVG Volume (30 Days)
238.6K
562.4K
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.73
$4.24
52 Week High
$7.48
$9.55

Technical Indicators

Market Signals
Indicator
AURA
BCYC
Relative Strength Index (RSI) 57.25 51.96
Support Level $5.83 $5.03
Resistance Level $6.73 $7.14
Average True Range (ATR) 0.41 0.31
MACD -0.00 0.07
Stochastic Oscillator 54.67 77.14

Price Performance

Historical Comparison
AURA
BCYC

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: